Applied Biosystems
Applied Biosystems is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Applied Biosystems.
Applied Biosystems is a company.
Key people at Applied Biosystems.
Key people at Applied Biosystems.
Applied Biosystems (ABI) pioneered automated instruments for protein sequencing and DNA analysis, revolutionizing biotechnology research. Founded in 1981, it developed landmark tools like the Model 470A Protein Sequencer and Model 370A DNA Sequencing System, enabling rapid gene discovery and molecular analysis for scientists in academia, pharma, forensics, and diagnostics.[1][2] Acquired multiple times—first by Perkin-Elmer in 1993, then merged into Life Technologies in 2008, and fully into Thermo Fisher Scientific in 2014—ABI now operates as a key brand under Thermo Fisher, serving global research needs in genomics, PCR, genotyping, and RNA analysis with products like TaqMan assays and Ion Torrent sequencers.[1][2][4]
The company addressed core bottlenecks in biotech: manual, labor-intensive sequencing of proteins and DNA. Its instruments automated these processes using fluorescent tags and nucleic acid extraction, boosting efficiency for drug discovery, stem cell research, and forensic applications. By 1986, revenues hit nearly $52 million, scaling to contribute to Life Technologies' $3 billion+ sales by 2008.[1][5]
Applied Biosystems traces to 1981 in Foster City, California, founded as Genetic Systems Company (GeneCo) by Hewlett-Packard scientist-engineers Sam Eletr and André Marion, leveraging DNA synthesis tech from Leroy Hood and Marvin H. Caruthers.[1] In 1982, it rebranded as Applied Biosystems and launched its first product, the Model 470A Protein Sequencer, generating $402,000 in revenue with 40 employees.[1]
Growth accelerated: By 1983, employee count doubled to 80, it went public on NASDAQ (ABIO), and revenues reached $5.9 million, adding fluorescent tags for assays.[1] André Marion became CEO in 1986 amid 45% sales growth to $52 million and launches like the game-changing Model 370A DNA Sequencer.[1] Acquisitions reshaped it—Perkin-Elmer in 1993 (as PE Applied Biosystems), spin-off as Applera in 2000, merger into Life Technologies (with Invitrogen) in 2008, and Thermo Fisher buyout in 2014—evolving from standalone innovator to integrated giant.[1][2]
Applied Biosystems rode the genomics revolution of the 1980s-90s, powering the Human Genome Project and democratizing DNA sequencing amid exploding biotech demand.[1][4] Timing was ideal: Post-1970s recombinant DNA breakthroughs needed automation, which ABI provided just as pharma invested billions in gene-based drugs.[1]
Market forces like rising R&D in personalized medicine, forensics, and agrotech favored its tools—e.g., PCR and sequencers became staples for COVID-19 testing and cancer genomics.[2][4] As part of Thermo Fisher, it influences the ecosystem by partnering with scientists on polygenic scores and AI-driven bioinformatics, enabling firms like Cytox for Alzheimer's prediction and sustaining 40 years of "history-defining breakthroughs."[4]
Thermo Fisher's Applied Biosystems brand will expand in precision medicine and multi-omics, leveraging Ion Torrent for cheaper, faster sequencing amid AI integration for data analysis.[2][4] Trends like polygenic risk scoring (e.g., saving millions via early interventions) and global health crises will drive demand, with bioinformatics heads like Jeanette Schmidt emphasizing customer collaboration.[4]
Influence evolves toward hybrid hardware-software ecosystems, influencing startups in synthbio and diagnostics. From its 1982 sequencer debut, ABI remains biotech's backbone—scaling discoveries that redefine human health.[1][4]